ReviewHeliyon2024
Stability, challenges, and prospects of chitosan for the delivery of anticancer drugs and tissue regenerative growth factors.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Integrating Cells, Biomaterials, and Advanced Engineering for Next-Generation Peripheral Nerve Repair.Cells, tissues, organs · 2026Review
- Nanochitosan-based adsorbents for sustainable treatment of palm oil mill effluent.RSC advances · 2026Review
- Recent Advances and Applications of Chitin and Chitosan Hydrogel Scaffolds in Tissue Engineering.Gels (Basel, Switzerland) · 2026Review
- AI-enabled, QbD-aligned Predictive, and Sustainable Design of Natural Polymer-based Drug Delivery Systems.AAPS PharmSciTech · 2026Review
- Article
- Bio-Polymers Based Functionalized Hydrogel Carriers for Targeted Oncology Therapies: Current Progress and Future Perspectives.International journal of nanomedicine · 2026Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chitosan, a biopolymer derived from chitin, offers significant potential for regulated anticancer drug administration and tissue regeneration growth factors, owing to its biocompatibility, low toxicity, biodegradability, and little immunogenicity. Moreover, its structure can be extensively modified, for example, to create scaffolds, hydrogels, nanoparticles, and membranes, allowing it to be engineered precisely to achieve specific outcomes However, the therapeutic utilisation of chitosan is impeded by significant challenges, such as its inadequate hemocompatibility, durability, and uniformity in commercial manufacturing. Additionally, there is insufficient research offering a thorough examination of the capabilities, limitations, and challenges related to chitosan as carriers for anticancer drugs and growth factors. This article examines the stability, challenges, and advanced application of chitosan as a drug carrier in anti-cancer therapy and growth factor delivery. The problems of unregulated chitosan degradation arising from unsuitable storage conditions are considered and potential solutions, and areas for future research, are proposed to deal with such problems. Consequently, this review is expected to be highly valuable for aspiring scientists studying chitosan-related systems for delivery of anti-cancer drugs and growth factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.